Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate
May 19 2022 - 2:00PM
Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”) a biopharmaceutical company developing vaccines,
announces a collaboration with the multidisciplinary Center for
R&D in Immunobiologics (“CeRDI”), an initiative of Instituto
Butantan (“Butantan”). Through this partnership, Butantan, a
leading Brazilian producer of immunobiologic products and vaccines,
and BWV will develop the universal influenza vaccine candidate,
BWV-101, in Brazil.
Instituto Butantan was approved for a grant from The State of
Sao Paulo Research Foundation (FAPESP) to develop BWV’s universal
influenza vaccine candidate in Brazil. This project grant is part
of a larger consortium across CeRDI to develop a centralized
resource to achieve national autonomy in vaccines and biologics
manufacturing and development. The consortium includes multiple
research groups across universities, including the University of
Oxford, along with other private companies. Through this
collaboration, CeRDI commits to advance vaccines based on the
adjuvant formulation and newer cell-culture based vaccines.
"We are incredibly honored to enter into this joint effort to
develop our vaccine candidate in Brazil,” said Joseph Hernandez,
Chairman and CEO of Blue Water Vaccines. “Instituto Butantan is a
leading producer of vaccines in Brazil and is highly respected
globally. We hope to scale new heights in vaccine manufacturing and
development through this collaboration.”
Blue Water Vaccines is developing a universal influenza vaccine
that could potentially provide lifelong protection from influenza,
including pandemic strains like the 1918 pandemic and 2009 swine
flu. Scientists from the University of Oxford identified epitopes
of limited variability in the head domain of the haemagglutinin
protein. These epitopes are targeted naturally by the immune system
and vaccination studies have shown that regions of influenza
viruses that circulated in 2006 and 1977 were able to protect
against infection with an influenza virus that last circulated in
1934.
The vaccine is being produced using an E. coli expression
platform allowing for a more cost effective and rapid production of
the vaccine, compared to the current influenza production
models.
About Blue Water Vaccines
Blue Water Vaccines, Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical Center
(CCHMC), and St. Jude Children's Hospital. The company is
developing a universal flu vaccine that will provide protection
from all virulent strains in addition to licensing a novel
norovirus (NoV) S&P nanoparticle versatile virus-like particle
(VLP) vaccine platform from CCHMC to develop vaccines for multiple
infectious diseases, including norovirus/rotavirus and malaria,
among others. Additionally, Blue Water Vaccines is developing a
Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed
to specifically prevent the highly infectious middle ear
infections, known as Acute Otitis Media (AOM), in children. For
more information, visit www.bluewatervaccines.com.
About Instituto Butantan
Instituto Butantan is the main producer of immunobiological
products and vaccines in Brazil. Instituto Butantan carries out
scientific missions domestically and abroad through the Pan
American Health Organization, the World Health Organization, UNICEF
and the United Nations. The Institute collaborates with other
agencies of the São Paulo State Secretariat of Health and the
Brazilian Ministry of Health for the improvement of overall health
in Brazil. It acts in partnership with various companies,
universities and philanthropic entities for the achievement of its
institutional objectives in public health. For more information
please visit the Institute website at www.butantan.gov.br or
contact the press office at (+55 11) 2627-9606 / 9866 /
9426 or email to imprensa@butantan.gov.br.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates, including, but not limited to BWV-301;
the failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of
clinical development of our product candidates; our need for
additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any vaccine under development, there are significant risks in the
development, regulatory approval and commercialization of new
products. BWV does not undertake an obligation to update or revise
any forward-looking statement. Investors should read the risk
factors set forth in BWV’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2021, filed with the Securities and
Exchange Commission (the “SEC”) on March 31, 2022, and periodic
reports filed with the SEC on or after the date thereof. All of
BWV’s forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Contact Information:Media Relations513-620-4101Email:
media@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2023 to Sep 2024